On April 26, 2023 Aravive, Inc. (Nasdaq: ARAV, "the Company"), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, reported the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually (Press release, Aravive, APR 26, 2023, View Source [SID1234630531]). In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
Presenter: Kathryn Beckermann, MD, PhD
Abstract Number: 4534
Format/Session: Poster; Genitourinary Cancer—Kidney and Bladder
Session Date/Time: Saturday, June 3, 2023, 8:00 AM – 11:00 AM CDT

Title: Phase 1b Batiraxcept (AVB-S6-500, BT) plus Gemcitabine (G) and Nab-paclitaxel (NP) as first-line treatment (1L) for pancreatic adenocarcinoma (PDAC)
Abstract Number: e16258
Format/Session: Publication Only

The poster will be available on the "Publications" section of the Aravive website when the ASCO (Free ASCO Whitepaper) embargo is released on May 25, 2023 at 4:00 PM CDT.